Cargando…

Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers

Antibody–drug conjugates (ADCs) are targeted therapeutics generated by conjugation of cytotoxic small molecules to monoclonal antibodies (mAbs) via chemical linkers. Due to their selective delivery of toxic payloads to antigen-positive cancer cells, ADCs demonstrate wider therapeutic indexes compare...

Descripción completa

Detalles Bibliográficos
Autor principal:	Peng, Haiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Mini review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597957/ https://www.ncbi.nlm.nih.gov/pubmed/34805745 http://dx.doi.org/10.1093/abt/tbab023

Ejemplares similares

ROR1, an embryonic protein with an emerging role in cancer biology
por: Borcherding, Nicholas, et al.
Publicado: (2014)

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2021)

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
por: Kim, S Y, et al.
Publicado: (2015)

Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies
por: Lee, Boon kiat, et al.
Publicado: (2022)

Drug Delivery of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) to Target Brain Tumors
por: Mehrdadi, Soheil
Publicado: (2023)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
por: Collin, Frédéric, et al.
Publicado: (2011)

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
por: Rebagay, Guilly, et al.
Publicado: (2012)

ROR1 and ROR2 expression in pancreatic cancer
por: Liu, Dongli, et al.
Publicado: (2021)

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
por: Kondrashov, Aleksei, et al.
Publicado: (2023)

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
por: Esapa, Benjamina, et al.
Publicado: (2023)

COVID-19 vaccine development from the perspective of cancer patients
por: He, Yang, et al.
Publicado: (2021)

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion
por: Henry, Claire, et al.
Publicado: (2015)

Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1
por: Islam, Syed S., et al.
Publicado: (2019)

Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
por: Jonasch, Eric, et al.
Publicado: (2023)

Detection and quantification of anti-rabies glycoprotein antibodies: current state and perspectives
por: Rodriguez, Maria Celeste, et al.
Publicado: (2021)

Targeted drugs and Psycho-oncological intervention for breast cancer patients
por: D’Abramo, Flavio, et al.
Publicado: (2016)

Personalized medicine in hematology — A landmark from bench to bed
por: Badalian-Very, Gayane
Publicado: (2014)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

Strengths and weaknesses of pneumococcal conjugate vaccines
por: Micoli, Francesca, et al.
Publicado: (2023)

Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations
por: Chan, Marion M., et al.
Publicado: (2018)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Book Review: Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer
por: Dhakal, Dipesh, et al.
Publicado: (2017)

Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates
por: Kang, Min Sun, et al.
Publicado: (2021)

Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective
por: Dahlgren, David, et al.
Publicado: (2020)

Urology training in the developing world: The trainers’ perspective
por: Ather, M. Hammad, et al.
Publicado: (2014)

Antibody-drug conjugates: the clinical development in gastric cancer
por: Zhu, Yingze, et al.
Publicado: (2023)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
por: Song, Chi Hun, et al.
Publicado: (2023)

Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID
por: Narayanan, J., et al.
Publicado: (2023)

COVID-19 Drug Development
por: Kim, Seungtaek
Publicado: (2022)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells
por: Yin, Zhengna, et al.
Publicado: (2017)

Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules?
por: Nessler, Ian, et al.
Publicado: (2018)

Computational approaches in target identification and drug discovery
por: Katsila, Theodora, et al.
Publicado: (2016)

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Therapeutic antibodies under development for SARS‐CoV‐2
por: Ma, Zetong, et al.
Publicado: (2021)

Computational selection of antibody-drug conjugate targets for breast cancer
por: Fauteux, François, et al.
Publicado: (2015)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
por: Aggarwal, Devesh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bi0vg3sb11md5a925317r3cbj6